Oncogenic BRAF Alterations and Their Role in Brain Tumors
Alterations of the v-raf murine sarcoma viral oncogene homolog B (BRAF) have been extensively studied in several tumor entities and are known to drive cell growth in several tumor entities. Effective targeted therapies with mutation-specific small molecule inhibitors have been developed and establis...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/6/794 |
id |
doaj-62b0caac3ce14ce785a17481f2911df1 |
---|---|
record_format |
Article |
spelling |
doaj-62b0caac3ce14ce785a17481f2911df12020-11-25T01:52:00ZengMDPI AGCancers2072-66942019-06-0111679410.3390/cancers11060794cancers11060794Oncogenic BRAF Alterations and Their Role in Brain TumorsFelix Behling0Jens Schittenhelm1Department of Neurosurgery, Eberhard Karls University Tübingen, 72074 Tübingen, GermanyDepartment of Neuropathology, Comprehensive Cancer Center Tübingen-Stuttgart and Eberhard Karls University Tübingen, Abt. für Neuropathologie, Calwer Str.3, 72074 Tübingen, GermanyAlterations of the v-raf murine sarcoma viral oncogene homolog B (BRAF) have been extensively studied in several tumor entities and are known to drive cell growth in several tumor entities. Effective targeted therapies with mutation-specific small molecule inhibitors have been developed and established for metastasized malignant melanoma. The BRAF V600E mutation and KIAA1549-BRAF fusion are alterations found in several brain tumors and show a distinct prognostic impact in some entities. Besides the diagnostic significance for the classification of central nervous system tumors, these alterations present possible therapy targets that may be exploitable for oncological treatments, as it has been established for malignant melanomas. In this review the different central nervous system tumors harboring BRAF alterations are presented and the diagnostic significance, prognostic role, and therapeutic potential are discussed.https://www.mdpi.com/2072-6694/11/6/794BRAF V600EKIAA1549-BRAFMAPKastrocytomaglioblastoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Felix Behling Jens Schittenhelm |
spellingShingle |
Felix Behling Jens Schittenhelm Oncogenic BRAF Alterations and Their Role in Brain Tumors Cancers BRAF V600E KIAA1549-BRAF MAPK astrocytoma glioblastoma |
author_facet |
Felix Behling Jens Schittenhelm |
author_sort |
Felix Behling |
title |
Oncogenic BRAF Alterations and Their Role in Brain Tumors |
title_short |
Oncogenic BRAF Alterations and Their Role in Brain Tumors |
title_full |
Oncogenic BRAF Alterations and Their Role in Brain Tumors |
title_fullStr |
Oncogenic BRAF Alterations and Their Role in Brain Tumors |
title_full_unstemmed |
Oncogenic BRAF Alterations and Their Role in Brain Tumors |
title_sort |
oncogenic braf alterations and their role in brain tumors |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2019-06-01 |
description |
Alterations of the v-raf murine sarcoma viral oncogene homolog B (BRAF) have been extensively studied in several tumor entities and are known to drive cell growth in several tumor entities. Effective targeted therapies with mutation-specific small molecule inhibitors have been developed and established for metastasized malignant melanoma. The BRAF V600E mutation and KIAA1549-BRAF fusion are alterations found in several brain tumors and show a distinct prognostic impact in some entities. Besides the diagnostic significance for the classification of central nervous system tumors, these alterations present possible therapy targets that may be exploitable for oncological treatments, as it has been established for malignant melanomas. In this review the different central nervous system tumors harboring BRAF alterations are presented and the diagnostic significance, prognostic role, and therapeutic potential are discussed. |
topic |
BRAF V600E KIAA1549-BRAF MAPK astrocytoma glioblastoma |
url |
https://www.mdpi.com/2072-6694/11/6/794 |
work_keys_str_mv |
AT felixbehling oncogenicbrafalterationsandtheirroleinbraintumors AT jensschittenhelm oncogenicbrafalterationsandtheirroleinbraintumors |
_version_ |
1724995456645201920 |